Podcasts about cancer drugs

A cancer patient relying on the kindness of strangers to fund life extending cancer medication wants to know why he's still waiting for Pharmac to deliver drugs the government committed to funding five months ago. After flip flopping on an election commitment; the government announced a 600 million dollar funding boost for cancer and other medications in June. It said seven of 13 drugs it promised on the election campaign would be covered and the others would be replaced by alternatives. Lung cancer drug Tagrisso or Osimertinib was supposed to be one of the first rolled out. It's a relief for former taxi driver and cancer patient Akhil Chaudhary; he's been funding an average of $1300 a week to buy the drug himself. But Pharmac is yet to make a decision on funding and Akhil is still paying, he spoke to Lisa Owen.

In today's episode, you'll get to explore the world of early cancer detection with Dr. Azra Raza, a pioneering oncologist and professor of medicine. We discuss the anxiety-inducing issues surrounding current cancer screening methods like mammograms and colonoscopies and examine advanced alternatives such as GRAIL and Cologuard. Dr. Raza also shares her groundbreaking work in detecting "The First Cell" and explores the potential of biomarkers and wearable devices for early detection (check out her fascinating book on this topic for more invaluable information!). In a deeply personal segment, Dr. Raza opens up about her late husband's battle with leukemia and how it shaped her understanding of cancer. We'll also discuss the flaws in the current cancer research model, the financial struggles for innovative scientists, and the urgent need for better funding to accelerate progress. Dr. Azra Raza is the Chan Soon-Shiong Professor of Medicine and Clinical Director of The Edward P. Evans Foundation MDS Center at Columbia University in New York. A practicing oncologist seeing 30–40 cancer patients weekly, she directs a basic cancer research lab with hundreds of original publications in high-profile journals. Her life is dedicated to the prevention of all chronic diseases, including cancer, by early detection. She worked with President Clinton, designing breakthrough developments in science and technology, and with President Joe Biden for the Cancer Moonshot initiative. Her latest book is a national bestseller and has been translated into nine languages. Dr. Raza is now involved in First Cell Therapeutics, developing a specific antibody to target and remove the tumor macrophage hybrid cells that act as The First Cell giving rise to cancer.  Full show notes: https://bengreenfieldlife.com/firstcell Episode Sponsors: Aires Tech: Aires Tech is offering you a 30% discount at airestech.com/ben by using code BEN30. Wild Health: Get 20% off with code BEN at wildhealth.com/ben. FUM: Head to tryfum.com/BEN and use code BEN to get a free gift with your Journey Pack! Vivobarefoot: You can purchase yours today with an exclusive 20% discount by going to vivobarefoot.com/bengreenfield and using code BENG20. MOSH: Head to moshlife.com/BEN to save 20% off plus FREE shipping on either the Best Sellers Trial Pack or the new Plant-Based Trial Pack.See omnystudio.com/listener for privacy information.

Belief a controversial Health New Zealand decision on cancer drug funding - will shorten lives. Pharmac's giving free access to Keytruda for five types of cancer, but funding doesn't kick in for two months. Health NZ has scrapped a proposal to provide it the medication for people in need until then. Patient Voice Aotearoa's Malcolm Mulholland says he is gobsmacked. He told Heather du Plessis-Allan it's the cruellest decision he's seen Health NZ make, and will mean patients lives are cut short. LISTEN ABOVE  See omnystudio.com/listener for privacy information.

First, Indian Express' Apurva Vishwanath discusses how the Delhi High Court underlined that the Delhi policemen's actions in the 2020 Delhi riots amounted to a “hate crime” that was “motivated and driven by religious bigotry”.Next, Indian Express' Amitabh Sinha examines the environmental concerns surrounding the use of Artificial Intelligence (AI) and what Google's annual environmental report reveals (08:18).And in the end, Indian Express' Anonna Dutt tells us about three targeted cancer drugs being exempted from customs duty (14:25).Hosted, written and produced by Shashank BhargavaEdited and mixed by Suresh Pawar

Cancer doctors are welcoming the funding of 13 new cancer drugs, but say with potentially 175,000 cancer patients getting them in the first year, the system for administering them won't cope.

The 1st of October is the soonist Pharmac says it will be able to get much-needed cancer drugs available to people who need them following the announcement they'll be getting a 600 million dollar cash injection from the government, Pharmac CEO Sarah Fitt speaks to Susana Lei'ataua.

In this week's edition of Midweek Mediawatch, Hayden Donnell talks to Emile Donovan about the prime minister becoming his own hype man, a strange malfunction in RNZ's push notifications, and a grab bag of media business news.

Kia Ora Aotearoa! Welcome to The Working Group, New Zealand's top political podcast not funded by NZ on Air. I'm your host, Martyn Bradbury, editor of The Daily Blog. Joining me tonight: Ani O'Brien and Seeby Woodhouse, alongside Host Martin (Bomber) Bradbury and panelist Damien Grant. ---------------------------------------------------------------------------------------------------------------------- TEXT: Working to 3598 Check out the Social Media - https://bento.me/theworkinggroupSee omnystudio.com/listener for privacy information.

I think we can all see the Nats stuffed up the 13 cancer drugs announcement on so many levels.They should never have promised specific drugs, that's Pharmac's job. But having promised them for the first year, they shouldn't have then broken that promise by leaving them out of the Budget.  And then, it's never really a good look if you finally get dragged to delivering on your promise because of public outrage.But having said all of that - sometimes I think we get a little too caught up on the political shenanigans and not focus enough on the end point.And how good is the end point? We have just had the single biggest injection of cash into Pharmac ever, we've had more cancer drugs than ever promised to be delivered in one go.That announcement yesterday of 54 new drugs wiped more a third off Pharmac's wishlist.Between the $600 million yesterday and the $1.7 billion announced in the Budget, this Government - which hasn't even been in power for 9 months - has pumped $2.3 billion into Pharmac.Now, I'm of the view that Pharmac is one of the most important things any Government funds, because it is literally the difference for some people between life and death. And those people are people who, more often that not, have paid their taxes diligently and just been good people. And good, normal, law-abiding Kiwis, I think, deserve access to as many drugs to save their lives as other people in the western world.I will never complain about Pharmac getting more money, however we end up in that situation.So in the end, I'm weirdly grateful for National stuffing this up, because we've ended up funding 54 new drugs we didn't have funded a couple of days ago. And that's the thing that really matters, isn't it? LISTEN ABOVESee omnystudio.com/listener for privacy information.

An excellent outcome from a terrible process.  That's Medical Oncologist Chris Jackson's summation of Pharmac's latest funding boost.   The Government's committing $604 million to cover funding for 54 new medicines, including 26 cancer treatments.   Jackson says we have to be careful about implementation because dumping 26 cancer medicines into the system at once could create a capacity demand issue.   He told Mike Hosking that a number of cancer services around the country are already stretched.   Jackson says if we don't fund the infrastructure for them like chemo units, nurses, and the like, we'll end up with more waiting lists.   LISTEN ABOVE See omnystudio.com/listener for privacy information.

Prime Minister Christopher Luxon's praising himself for finally getting there with the cancer drug funding.   The Government's committing $604 million to Pharmac, taken from next year's Budget.   It will cover the funding for 54 new medicines, including up to seven of 13 drugs the Government promised last year.   The cancer medicines funded would treat cancer of the lung, liver, skin, bowel, kidney, head and neck, and bladder. The Government has also promised some of the drugs would combat breast and blood cancers.   The 28 non-cancer-related drugs would address a range of conditions likely to include infections, respiratory conditions, osteoporosis, sexual health, dermatology, inflammatory conditions, and mental health.   The spend was double what National proposed in 2023.  Luxon told Mike Hosking that he's proud of the investment and ultimately for delivering more than promised initially.   He says it's different from what was proposed but he's more interested in the outcomes, and he's now surpassed them.   LISTEN ABOVE See omnystudio.com/listener for privacy information.

On the Mike Hosking Breakfast Full Show Podcast for Tuesday 25th of June, we finally got the cancer drugs and what a haul! It's set to help tens of thousands more people.  We could have had an hour with the Prime Minister but in the time we had, we talked cancer drugs, the various infrastructure issues, and whether there is a hiring freeze for frontline doctors and nurses.  The Scott Robertson All Blacks era has begun! He joined Mike to talk the season ahead and what the team will look like under him.  Get the Mike Hosking Breakfast Full Show Podcast every weekday morning on iHeartRadio, or wherever you get your podcasts.  LISTEN ABOVE See omnystudio.com/listener for privacy information.

Sign-off for a huge Government funding boost for Pharmac - which would allow for greater access to potential life-changing drugs for cancer patients - could come as soon as Monday.   Finance Minister Nicola Willis has confirmed she would announce a policy “very shortly”, but wouldn't confirm the exact timing.   Willis was speaking to Newstalk ZB's Mike Hosking this morning, following reporting by The Post that an announcement of a $600 million boost for drug funding is imminent.   That money could allow National to keep its pre-election promise to fund life-saving cancer treatments, while also giving Pharmac more money for other drugs.   Willis told Hosking no announcement would be made today.   But she did not deny, when asked, that an announcement about drug funding would be made next week following Cabinet sign-off on Monday.   “We've been working very hard on this policy and we're going to make an announcement very shortly,” she told Hosking.   She did not specify whether the $600m figure was accurate.   Willis' comments come after the Government has been accused of breaking an election promise to fund 13 cancer-specific medicines, after this year's Budget did not include funding for the policy.   Health Minister Shane Reti has promised the drugs will still be funded and delivered this year.   That apparently put Reti at odds with Pharmac Minister David Seymour who this week said he could not guarantee funding for the specific 13 drugs listed in the National Party's election policy, partly because that would threaten Pharmac's negotiating ability.   However, an additional $600m would represent an almost 40 per cent increase in Pharmac's budget, which could give the drug-buying agency the freedom to buy the 13 cancer medicines along with other medications, maintaining its independence.   Health advocacy group Patient Voice Aotearoa described the pending policy as “excellent news, not only for terminally-ill cancer patients, but for many of the 330,000 New Zealanders who are waiting for one or more of the 90 medicines on Pharmac's Options for Investment List”.   “Today's news will put a significant dent in Pharmac's waiting list of medicines that they want to fund,” chair Malcolm Mulholland said.   “This is worth celebrating. I hope that today's news signals the end of New Zealand being the only country in the world with a waiting list of medicines.   “Having patients wait for years for a medicine not only leads to poorer health outcomes but is inhumane. It should be to our eternal shame that successive Governments underfunded Pharmac for over two decades which resulted in an ever-growing waiting list of medicines, and consequently, lives either being cut short or living in pain and misery.”   The policy, campaigned on by National ahead of the 2023 election, promised to fund 13 cancer treatments which were unavailable in New Zealand.   The list of drugs had been identified in a 2022 Cancer Control Agency report. Some experts and advocates, including those in that report, have questioned whether other or more modern drugs would be more effective.   The Budget this year didn't include funding for the policy, prompting widespread criticism and forcing the Government to come up with a solution to honour the commitment. No timeline has been offered regarding an announcement on the future of the policy, except that it would be implemented by the end of the year.   Reti, a National MP, earlier this week admitted the Government had poorly communicated the policy's future but he stood by his party's policy, guaranteeing the same 13 drugs would be funded.   “We had made a commitment to these people and they saw themselves in this policy and so we're going to deliver that policy.”  LISTEN ABOVE See omnystudio.com/listener for privacy information.

At a select committee hearing yesterday, Doctor Shane Reti doubled down on National's promise saying it would fund the specified drugs, but the cancer drug list he's working to is 3 years old and advocates say there are newer treatments, Onocologist, Doctor Chris Jackson speaks to Lisa Owen.

Doctor Nigel Patton, a blood cancer doctor, who has cancer himself, speaks to Lisa Owen about being one of an unknown number of kiwis forced to import un-funded cancer drugs from the likes of India, at a fraction of the cost they would otherwise be paying.

The astronomical cost of self funding cancer drugs raises questions about the role of medical insurance in Aotearoa which supposedly has a fully funded health system, Dr Stephen Child, the chief medical officer for insurer Southern Cross speaks to Lisa Owen.

As the government comes under increasing pressure for backtracking on an election promise to fund 13 cancer drugs.

Another group of cancer doctors is piling the pressure on the government to honour it's election promise to patients... It believes have so far been overlooked in drug funding decisions. Dr Rodger Tiedemann, a haematologist, is one of 50 specialists have signed another open letter to the government imploring it to also honour the pre-election promise to blood cancer patients. He spoke with Lisa Owen.

In this week's edition of Midweek Mediawatch, Hayden Donnell talks to Emile Donovan about the government's latest reason for not funding 13 cancer drugs, a mammoth loss expected at TVNZ, AI faking the news and even our contemporary history  - and a slight directed at the Ōtaki Today.

An expert says the Government should aim for the best drugs available, not be tied to an old list. National pledged to fund 13 cancer drugs during the election campaign, but didn't allocate any money in last week's Budget. The Prime Minister says an announcement on treatments will be made this year. Otago University Cancer Medicine Professor, Chris Jackson, says the list was based on what Australia has - that we don't. He says it didn't take such things as cost into account. "Personally, I would prefer saying - we've got this much money, and then letting Pharmac rank it and then get the best deals."  LISTEN ABOVE  See omnystudio.com/listener for privacy information.

Tonight on The Huddle, Kiwiblog contributor and Curia pollster David Farrar and Hauraki host and author Matt Heath joined in on a discussion about the following issues of the day - and more! Has the Government made the right call in promising to deliver on the promised cancer drugs that got left off last year's Budget? Are they u-turning after seeing the public reaction? Should they just leave it to Pharmac to make funding decisions? A new poll from the Guardian says over two-thirds of Australian voters think the age limit for social media should be raised from 13 to 16. Do we think this will work? The Police Commissioner believes shorter opening hours for liquor shops and higher prices are the answer to the nation's alcohol abuse issues. Is this the right solution? LISTEN ABOVE See omnystudio.com/listener for privacy information.

The Finance Minister promises there's been no change of mind when it comes to delivering on the promised cancer drugs.  The Government campaigned on spending about $280 million on 13 treatments, but the drugs weren't funded in last week's Budget. Nicola Willis says the Government will deliver on this commitment very soon.  "What we've had is a commitment to New Zealanders that we would fund those 13 cancer treatment drugs, and we are going to deliver on the commitment."  LISTEN ABOVESee omnystudio.com/listener for privacy information.

The Finance Minister says the government will keep its promise to fund more cancer treatments. Prime Minister Christopher Luxon spoke to Ingrid Hipkiss.

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world.## The healthcare industry is facing various challenges, including nursing homes suing to block a staffing mandate, healthcare organizations not being prepared for cyberattacks, the impact of Ascension's cyberattack, and a house committee targeting healthcare consolidation. Trends in addressing social determinants of health and site-neutral payments are also discussed. A report shows that over a third of healthcare organizations lack a cyberattack contingency plan. Stay informed on healthcare news and trends through the Healthcare Dive newsletter.## Data-driven marketing strategies are crucial for success in today's competitive landscape. Marketers are using data to optimize campaigns and gain insights into consumer behavior. Examples include Pop-Tarts Bites using data to improve ad recall and engagement rates. Legacy media investing in connected TV, retail media convergence, the impact of cookie deprecation on marketing strategies, and the latest trends in marketing data are also covered. Marketing Dive delivers this content to subscribers as part of their newsletter subscription.## AstraZeneca aims to expand its cancer drug sales, while Pfizer and Lilly enter the direct-to-consumer market online. The European Commission declines to revoke approval of PTC Duchenne drug, calling for a new review. Amgen's drug for tough-to-treat lung cancer receives FDA approval, and Regeneron faces new biosimilar threats. An AI biotech has laid off staff, with companies focusing on immune disease research and treatments. Moderna wins a patent dispute, Walgreens and CVS rethink their pharmacy business, and weight-loss drug shortages affect patients. Biopharma Dive provides news and insights on biotech and pharma trends.## AstraZeneca plans to achieve $80 billion in annual revenue by 2030, launching 20 new drugs before the end of the decade. Bio lays off 30 employees as Congress moves forward with the Biosecure Act. Lilly signs a potential $1.1 billion deal with Aktis Oncology for radiopharmaceuticals, GSK's long-acting asthma drug shows positive results in Phase III trials, FDA approves interchangeable biosimilars to Regeneron's Eylea, strong Phase III data for Dupixent by Sanofi and Regeneron, and AltruBio raises $225 million in Series B funding.## AstraZeneca invests $1.5 billion in an antibody-drug conjugate (ADC) manufacturing plant in Singapore. The global market for GLP-1 receptor agonists is projected to reach $125 billion by 2033. Gilead highlights positive results for a liver disease drug, while Rapport Therapeutics and Telix Pharma file for IPOs. Sino Biological offers recombinant cytokines for cell culture research. Bayer announces 1,500 layoffs as part of a company overhaul.## Humana CEO Bruce Broussard steps down on July 1, with current COO Jim Rechtin taking over. Inpatient admissions boost revenue for for-profit providers in Q1. The US increases tariffs on medical products from China to boost domestic production. Black Basta ransomware targets critical infrastructure providers, causing concern among authorities.## Bayer undergoes layoffs as part of a company shake-up led by CEO Bill Anderson. FogPharma and ArtBio collaborate on designing a new radiopharma drug. Sands Capital raises a $555 million fund for biotech 'crossover' investing.## Big pharma companies pledge $2.16 billion in investments in France to boost global manufacturing and research capabilities. Interest grows in cancer vaccines as a potential breakthrough in immunotherapy.## Ascension confirms a ransomware attack leaving its computer systems offline. Insurers see elevated utilization in Q1 with minimal financial impact from cyberattacks.## The biotech industry sees a surge in cell and gene therapy technologies with biosimilar uptake showing mixed results. Novartis' biosimilar sales grow while Boehringer Ingelheim's biosi

On the Mike Hosking Breakfast Full Show Podcast for Tuesday 4th of June, hooligans in Levin are the latest case of boy racer issues for rural New Zealand, and why are we spending so much on lockdown plans for schools?  The Prime Minister was in to defend the Government not putting the money in, yet, for new cancer drugs.  Andrew Saville and Guy Heveldt digested the long weekend of sports and how well our motorsport drivers are flying the flag for New Zealand.  Get the Mike Hosking Breakfast Full Show Podcast every weekday morning on iHeartRadio, or wherever you get your podcasts.  LISTEN ABOVE See omnystudio.com/listener for privacy information.

Last week's Budget announcement had National break one of their campaign promises.  Christopher Luxon says he understands people's frustration with the lack of funding for cancer drugs in last week's Budget.  National campaigned on spending about $280 million on 13 treatments in last year's election but was unable to include it in the Budget.  The Government says it's now working on a plan to fund the medicines.  The Prime Minister told Mike Hosking that the delay to funding is regrettable, but it's the result of the situation the Government has inherited from the last government.  He says $1.8 billion of Pharmac funding had been switched off, which the Government had to switch back on again.  Luxon's visiting Fiji and Niue this week, his first visit to the region as PM.  He says the Pacific is an important part of New Zealand's foreign policy.   He will meet with his counterpart in Fiji during a trip which will have significant trade and economic focus.   Luxon told Mike Hosking that it's a chance to build rapport with Niue.   He says Fiji is a chance to talk more about the security and economic interests we share.  LISTEN ABOVE See omnystudio.com/listener for privacy information.

Three great interviews today.  Murray Denyers has kidney cancer and has paid more than 200k for life-prolonging drugs. He says the govt has made a colossal cock up. Ok, so the budget is well and truly behind us and what lies ahead for the NZ economy and interest rates? What has the reaction been now the dust has settled how long will these tough times stay with us and when will Kiwis get a break from the high interest rate environment? Principal Economist at Infometrics Brad Olsen is with us. Finally, we talk sports… John Day is in  Super Rugby quarterfinals set Great weekend for Kiwi drivers in the USA T20 Cricket World Cup underway French Open rolls on into the quarterfinals Warriors team gets named at 6pm for Saturday's game against the Cowboys Don't forget we go live every weekday morning at 7:30  YouTube, Twitch, and Tik Tok.  All the other social, listen and watch links are here See omnystudio.com/listener for privacy information.

With Nicola Willis, Meka Whaitiri and Liam Hehir.

There's assurances from the Health Minister that he'll deliver on the promised cancer drug funding this term. The Government had pledged to put $280 million towards funding 13 life saving cancer treatments under Pharmac. But they didn't make the cut on Thursday's Budget, with Finance Minister Nicola Willis saying it hadn't been possible. Health Minister Shane Reti says he's sorry about the uncertainty it is causing cancer patients and their families. "We will fund those cancer drugs, and we'll be making more announcements soon on that. But we'll absolutely maintain our commitment to those people - who saw that expectation and what we campaigned on." LISTEN ABOVESee omnystudio.com/listener for privacy information.

A woman living with tumours on her heart says she's devastated the government's broken its promise to fund thirteen new cancer drugs. Health correspondent Rowan Quinn reports.

The Finance Minister says the recent culture of spraying the money gun with reckless abandon has come to an end.   Nicola Willis released the 2024 Budget yesterday, confirming the long-awaited tax cuts and announcing funding for various sectors and industries.  She confirmed that the tax programme is fully funded by the baseline-savings exercise of rooting out waste in government departments.  Willis told Mike Hosking that they're funding it responsibly, without needing to borrow funds.  The economy's forecasts have degraded in recent times, the Government books not predicted to return to surplus until the 2027/28 financial year.  If they hadn't made those cuts and changes, Willis said, they wouldn't be back into the black until 2031.  LISTEN ABOVE See omnystudio.com/listener for privacy information.

There was no room in today's Budget to fund the cancer drugs National promised during the election campaign. Patient Advocacy Aotearoa's Malcolm Mulholland says he's disappointed. "There are patients right now with terminal cancer who are waiting for these medicines to be funded - if they're not funded, to be perfectly blunt, some will die." LISTEN ABOVESee omnystudio.com/listener for privacy information.

Editor's Summary by Anne Rentoumis Cappola, MD, ScM, Associate Editor of JAMA, the Journal of the American Medical Association, for the May 7, 2024, issue.

Go behind the scenes of Trevor Blake's biotech companies as he discusses his mission to develop cancer treatments with reduced side effects at lower costs. Learn about the challenges and breakthroughs in his work to make a positive impact, how he sold his biotech company for over $100 million and his unique "hub model" that leverages vendors and contractors can help you grow your business faster and more efficiently. Learn more about your ad choices. Visit megaphone.fm/adchoices

How does physician empathy impact chronic pain outcomes? Find out about this and more in today's PeerDirect Medical News Podcast.

Injectable immunotherapy drugs can be made, in theory, but gravity prevents them from crystallizing correctly. A startup thinks the solution could be right above us. Read this story here. Learn more about your ad choices. Visit megaphone.fm/adchoices

Will we have societal collapse on 2024? Will there be an election? "A viler evil than to murder a man, is to sell him suicide as an act of virtue." - AYN RAND, ATLAS SHRUGGED ----- BraveTV Official Website: https://BraveTV.com Store: https://BraveTV.com/store Podcasts: https://BraveTV.com/watch About Dr. Jason Dean: https://BraveTV.com/about ----- BLACK November Special!! Work one-on-one with Dr. Jason Dean in his practice. You will get a Full New Patient Consult as well as a Report of Findings and an opportunity to work with Dr. Dean on your customized program for only $99 up front. You can also add a on a special DNA Report for just $297! Sign up HERE! www.workwithdrdean.com/qualify NEW SAVINGS!!! Full Moon Protocol $197 Today with PROMO Code BTV - SAVE over $20 Get your Full Moon Protocol at: https://bravetv.store/ The United States Federal Government has purchased over $200 MILLION in ANTIi-Radiation Medications for a coming Nuclear Event! Grab Your Pre-Sale Special Atomic Detoxified Iodine, a SPECIAL Edgar Cayce Formula! https://bravetv.store/products/pre-sale-bravetv-iodine-formula-will-ship-early-october-1-2-oz-size To change your retirement to Silver IRA's, be sure to check out my Plan for you at http://www.kirkelliottphd.com/DrDean For Vaccinated and Spike Protein Shedding, clean your arteries out with NEW Nattokinase and Vitamin C Power at https://bravetv.store/collections/bravetv-supplements Get CLEAN American Grasslands Beef for your family at http://mylibertybox.com/Drdean ----- BraveTV interviews prolific guests that are informative, funny, interesting, controversial, and enjoy Freedom of Speech to the fullest

KMOX Business Analyst Jerome Katz, SLU/Chaifetz School of Business Professor joins Tom and Megan discussing burger wars and cancer drugs.    Credit: © Fred Squillante/Columbus Dispatc / USA TODAY NETWORK

Today we're joined by Suzy Griswold, founder and director of HealingStrong, to talk about her journey from being diagnosed with cancer to finding healing through holistic methods. Suzy shares about her initial reaction to being told doctors had found a tumor and being diagnosed with cancer and about how her body reacted to the traditional treatment at first. We discuss the Gerson therapy protocol, an alternative treatment protocol for cancer, and how Suzy found that these alternative methods of detoxing actually healed her completely. We talk about what she learned about God and his faithfulness throughout her journey and share some alarming cancer statistics that reveal why medical professionals are so invested in cancer drugs. --- Timecodes: (02:09) Thyroid cancer diagnosis (08:20) Researching alternatives / Gerson therapy (17:16) Suzy's healing journey (23:01) Reintroducing things to diet/lifestyle (25:29) Coffee enemas (29:30) Spiritual transformation (34:50) Doctors and pharma issues (46:07) Tumors (51:10) Commitment to changes --- Today's Sponsors: We Heart Nutrition — nourish your body with research-backed ingredients in your vitamins at WeHeartNutrition.com and use promo code ALLIE for 20% off. WNG Online — God's World News is primarily designed for students. Get 50% off an annual subscription at GWNews.com/ALLIE. Good Ranchers — subscribe and get over two pounds of chicken breast for FREE plus $20 off your first order at GoodRanchers.com – make sure to use code 'ALLIE' when you subscribe. Carly Jean Los Angeles — use promo code RELATABLE25 for $25 off an order of $125 or more, or RELATABLE50 for $50 off an order of $200 or more at CarlyJeanLosAngeles.com! --- Relevant Episodes: Ep 693 | The Disturbing Truth About Breast Cancer Awareness Month | Guest: Chris Wark (Chris Beat Cancer) https://podcasts.apple.com/us/podcast/ep-693-the-disturbing-truth-about-breast-cancer/id1359249098?i=1000583065318 Ep 741 | How to Realistically Live Toxin-Free | Guest: Taylor Dukes https://podcasts.apple.com/us/podcast/ep-741-how-to-realistically-live-toxin-free-guest-taylor/id1359249098?i=1000595318788 --- Buy Allie's book, You're Not Enough (& That's Okay): Escaping the Toxic Culture of Self-Love: https://alliebethstuckey.com/book Relatable merchandise – use promo code 'ALLIE10' for a discount: https://shop.blazemedia.com/collections/allie-stuckey Learn more about your ad choices. Visit megaphone.fm/adchoices

Tune in to the latest episode of the GOLD podcast which sees Isabel sit down for a chat with Wendy Bartie, Senior Vice President and General Manager, US Hematology and Cell Therapy, Bristol Myers Squibb. In the episode, Wendy discusses her passion for developing life-saving cancer drugs with less toxic side effects. Learn about how far the industry has come, while being guided through the ways in which the sector could still evolve for the benefit of patients. If you're interested in learning more about the topic areas discussed in this episode, check out the following content: Going for gold in gynaecological cancers Mental health matters in pharma's approach to care Last week's podcast: A high-speed chase for oncology innovation

David Young, President of R&D at Processa Pharmaceuticals, talks about the FDA's Project Optimus draft guidance on optimal dosage regimens for specific patients. Processa is modifying existing cancer-killing molecules to improve efficacy and decrease side effects by taking into account genetic factors and the benefit-risk profile of each patient. This precision medicine approach will inform clinical trial recruitment, dosing regimens and the number of patients who can be effectively helped.   David explains, "There are a couple of things that make us unique. One is that we're taking the active cancer-killing molecules on the market. It's a given drug that's approved by the FDA, and we know it kills cancer. We've taken that molecule and either changed it slightly or administered it with another drug in some way to decrease or change the drug's metabolism and then to distribute more drug to the cancer cell."   "So, we started to learn how they look at the benefit-risk profile, and we started to develop our version of regulatory science, and that's expanded now over the last 30 years. That expansion into regulatory science now encompasses Project Optimus, which the FDA recently has put out draft guidance on in terms of optimal dosage regimens. They as well put out some documentation on the Project Optimus initiative where you go in to determine the optimal regimen for your patient. Not just any regimen, but the optimal regimen for your patients. If you get an optimal regimen for your patients, maybe that has a certain balance of efficacy and safety. You might come up with something different than we used to do five years ago in terms of the dosage regimen." #ProcessaPharmaceuticals #ProjectOptimus #BenefitRiskProfile #Cancer #PrecisionMedicine #ClinicalTrials processapharmaceuticals.com Download the transcript here  

David Young, President of R&D at Processa Pharmaceuticals, talks about the FDA's Project Optimus draft guidance on optimal dosage regimens for specific patients. Processa is modifying existing cancer-killing molecules to improve efficacy and decrease side effects by taking into account genetic factors and the benefit-risk profile of each patient. This precision medicine approach will inform clinical trial recruitment, dosing regimens and the number of patients who can be effectively helped.   David explains, "There are a couple of things that make us unique. One is that we're taking the active cancer-killing molecules on the market. It's a given drug that's approved by the FDA, and we know it kills cancer. We've taken that molecule and either changed it slightly or administered it with another drug in some way to decrease or change the drug's metabolism and then to distribute more drug to the cancer cell."   "So, we started to learn how they look at the benefit-risk profile, and we started to develop our version of regulatory science, and that's expanded now over the last 30 years. That expansion into regulatory science now encompasses Project Optimus, which the FDA recently has put out draft guidance on in terms of optimal dosage regimens. They as well put out some documentation on the Project Optimus initiative where you go in to determine the optimal regimen for your patient. Not just any regimen, but the optimal regimen for your patients. If you get an optimal regimen for your patients, maybe that has a certain balance of efficacy and safety. You might come up with something different than we used to do five years ago in terms of the dosage regimen." #ProcessaPharmaceuticals #ProjectOptimus #BenefitRiskProfile #Cancer #PrecisionMedicine #ClinicalTrials processapharmaceuticals.com Listen to the podcast here  

In this episode, we review the high-yield topic of ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Cancer Drugs Overview⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠from the Oncology section. Follow ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Medbullets⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ on social media: Facebook: www.facebook.com/medbullets Instagram: www.instagram.com/medbulletsofficial Twitter: www.twitter.com/medbullets --- Send in a voice message: https://podcasters.spotify.com/pod/show/medbulletsstep1/message

Treating cancer has become increasingly difficult as cells develop resistance. Northwestern investigators have sought to address this issue on the cellular level through the development of a novel FateMap tool, used to predict the future behavior of cancer cells before they are exposed to cancer-fighting drugs. In this episode, Yogesh Goyal, PhD, discusses his latest research, published in Nature, and how his lab is addressing complex problems through an interdiscplinary approach. 

The Atlantic examines how economic issues are making critical cancer drugs hard to find. The push to tie Medicaid to work is making a comeback. Georgia is at the forefront. The Washington Post has the story. Amy Olson is playing in the U.S. Women’s Open while seven months pregnant. The Wall Street Journal looks at how she’s doing it.

And the FDA releases new guidance for testing psychedelic drugs…. Headlines: – Putin Tries to Reassert Control After Rebellion (04:10) – Shortage of Life-Saving Cancer Drugs (14:55) – Heat Dome Across Southern US: SEE MAP (21:30) – Biden Announces $42 Billion To Get All Americans High-Speed Internet (24:22) – Controversial Plan to Release Radioactive Fukushima Water into Sea (27:20) – FDA Released Draft Guidance for Clinical Trials Testing Psychedelic Drugs (31:45) – 7 Planets in Retrograde: What This Means For Your Sign (LINK) (34:00) – On This Day In History (38:20) – **Mo News Premium For Extra Content, Private Podcast: (Click To Join)** – Mosheh Oinounou (@mosheh) is an Emmy and Murrow award-winning journalist. He has 20 years of experience at networks including Fox News, Bloomberg Television and CBS News, where he was the executive producer of the CBS Evening News and launched the network's 24 hour news channel. He founded the @mosheh Instagram news account in 2020 and the Mo News podcast and newsletter in 2022. Jill Wagner (@jillrwagner) is an Emmy and Murrow award- winning journalist. She's currently the Managing Editor of the Mo News newsletter and previously worked as a reporter for CBS News, Cheddar News, and News 12. She also co-founded the Need2Know newsletter, and has made it a goal to drop a Seinfeld reference into every Mo News podcast. Follow Mo News on all platforms: Instagram: https://www.instagram.com/mosheh/ Twitter: https://twitter.com/mosheh Facebook: https://www.facebook.com/MoshehNews Snapchat: https://t.snapchat.com/pO9xpLY9 Youtube: https://www.youtube.com/@monews TikTok: https://www.tiktok.com/@mosheh Learn more about your ad choices. Visit megaphone.fm/adchoices

Some chemotherapy drugs are currently in such short supply in the U.S. that doctors are going to extreme lengths to get patients the treatments they need. The shortage is fueling new calls to fortify the U.S. drug supply chain. Plus, the Fed ends its rate hike streak. And, record numbers of people have been forcibly displaced worldwide. Guests: Axios' Tina Reed, Matt Phillips and Laurin-Whitney Gottbrath. Credits: Axios Today is produced by Niala Boodhoo, Alexandra Botti, Fonda Mwangi, Lydia McMullen-Laird and Alex Sugiura. Music is composed by Evan Viola. You can reach us at podcasts@axios.com. You can text questions, comments and story ideas to Niala as a text or voice memo to 202-918-4893. Go deeper: Cancer drug shortages highlight supply chain vulnerabilities Federal Reserve holds interest rates steady, signals more hikes ahead Record 110 million people forcibly displaced worldwide, UN says Learn more about your ad choices. Visit megaphone.fm/adchoices

This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit www.sensible-med.com/subscribe

Our colleague Lizzy Lawrence joins us to explain the shocking story of a medical device company that sold fake implants and the warped system that made the scam lucrative. We'll also preview the year's biggest cancer research meeting and discuss a surprising twist with novel weight loss medicines.

Cost of Cancer drugs - VP's lecture